Phase 1 and 2 trials show J&J COVID vaccine safe, immune-producingInterim phase 1-2a results from Johnson & Johnson's COVID-19 vaccine trials show that its vaccine, Ad26.COV2.S, produces a good immune response and safety profile, according to a New England Journal of Medicine study yesterday.Unlike the two messenger-RNA vaccines currently in use in the United States, the Johnson & Johnson vaccine uses a recombinant, non-replicating adenovirus 26 (Ad26) with a complete and stabilized spike protein."A single dose of Ad26.COV2.S elicited a strong humoral response in a majority of vaccine recipients, with the presence of S-binding and neutralizing antibodies in more than 90% of participants, regardless of either age group or vaccine dose,"